Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Following a modified Atkins diet high in fat and low in carbohydrates and taking medication may reduce seizures by over half in people with tough-to-treat epilepsy, according to a study by researchers at the <keyword id="6365231" type="General" weightage="80" keywordseo="all-india-institute-of-medical-sciences" source="Orion">All India Institute of Medical Sciences</keyword>. The modified Atkins diet is a combination of the Atkins diet and a ketogenic diet that includes food items such as soy products, heavy cream, butter and oils, leafy green vegetables, and animal protein including eggs, chicken, fish, and bacon. While the ketogenic diet has been shown to be effective in reducing seizures, its stringent requirements and restrictions can make it difficult to follow, the researchers said. "For people with drug-resistant epilepsy, or those who have been unable to find an effective treatment to reduce seizures, it's encouraging to see that there are lifestyle changes that can be combined with standard drug therapy to reduce the number of seizures," said <keyword id="2194193" type="General" weightage="80" keywordseo="manjari-tripathi" source="Orion">Manjari Tripathi</keyword>, from AIIMS <keyword id="6358777" type="General" weightage="20" keywordseo="new-delhi" source="Orion">New Delhi</keyword>. "Our study found that this combination may reduce the chance of seizures by more than half," said Tripathi, author of the study published in the journal <keyword id="72938" type="General" weightage="20" keywordseo="neurology" source="Orion">Neurology</keyword>. The study involved 160 adults and adolescents who had epilepsy for more than 10 years on average and had at least 27 seizures per month despite trying an average of four antiseizure medications at the maximum tolerated dose. They were randomly assigned to receive either standard drug therapy alone or drugs plus the modified Atkins diet over six months. Participants logged their seizures and meals. They were given food lists, sample menus and recipes. Carbohydrate intake was restricted to 20 grams per day. <keyword id="914284" type="General" weightage="80" keywordseo="us-federal" source="Orion">US Federal</keyword> dietary guidelines recommend between 225 and 325 grams of carbs per day. After six months, researchers found that 26 per cent of people who had both drug therapy and followed the modified Atkins diet had more than a 50 per cent reduction in seizures compared to only three per cent of the people who had drug therapy alone. Four people in the diet group were free of seizures by the end of the study, while no one in the medication-only group was seizure-free, the researchers found. The study also looked at the quality of life, behaviour and side effects at six months. The group that had drug therapy and followed the modified Atkins diet showed an improvement in all areas compared to the group that had drug therapy alone, the researchers said. They noted that 33 per cent of the participants did not complete the study due to poor tolerance of the diet, lack of benefits or the inability to follow up in part due to COVID-19. However, the researchers said tolerance of the modified Atkins diet was better than what is seen with the ketogenic diet. "While the modified Atkins diet may be an effective treatment in controlling seizures, further research is needed to identify genetic biomarkers and other factors associated with the response to this diet," Tripathi added. "This may improve patient care by encouraging targeted precision based earlier use of this diet," she added. The researchers acknowledged a limitation in the study that seizures were self-reported or reported by caregivers, so some of them may not have been reported at all. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/how-covid-can-disturb-your-sleep-and-dreams-and-what-could-help/articleshow/96783538.cms">How Covid can disturb your sleep and dreams and what could help</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/indias-decennial-census-to-be-delayed-further-say-officials/articleshow/96784633.cms">India's decennial census to be delayed further say officials</a>

High fat, low carb diet along with medicines can cut seizures by half: AIIMS study

<ul><li>2.3 million newborns die of severe bacterial infections each year, the experts said in a report published in the December 2022 Bulletin of the <keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword>.</li><li>Over the last decade, <keyword id="149212" type="General" weightage="80" keywordseo="amr" source="Orion">AMR</keyword> has worsened to the point where around 50-70 per cent of common pathogens show a high degree of resistance to available first and second-line antibiotics, they said.</li><li>According to the report, ethical concerns, logistical issues and regulatory requirements have made it difficult to conduct clinical research in newborns.</li></ul>There is an urgent need to develop antibiotics for newborn babies, a population that is particularly vulnerable to antibiotic resistance, according to leading global public health experts including those from India. Recent estimates show about 2.3 million newborns die of severe bacterial infections each year while an increasing number are becoming resistant to currently used antibiotics, the experts said in a report published in the December 2022 Bulletin of the World Health Organization. Over the last decade, AMR has worsened to the point where around 50-70 per cent of common pathogens show a high degree of resistance to available first and second-line antibiotics, they said. The paper is co-authored by international experts in the field of antimicrobial resistance (AMR), including those from the Global Antibiotic Research &amp; Development Partnership (GARDP) and <keyword id="6365231" type="General" weightage="50" keywordseo="all-india-institute-of-medical-sciences" source="Orion">All India Institute of Medical Sciences</keyword> (<keyword id="40458" type="General" weightage="50" keywordseo="aiims" source="Orion">AIIMS</keyword>). The authors noted that despite substantial progress in medical research and a steep decline in the number of children under the age of five who die of preventable diseases, many problems related to child health remain to be tackled. Severe bacterial infections are one of them. "There is an urgent need to identify high priority antibiotics to understand which ones work best and safely in children, and then make them available where they are needed," said <keyword id="15914044" type="General" weightage="50" keywordseo="mike-sharland" source="Orion">Mike Sharland</keyword> from St George's, <keyword id="125994" type="General" weightage="50" keywordseo="university-of-london" source="Orion">University of London</keyword> (SGUL), and member of the <keyword id="15914043" type="General" weightage="50" keywordseo="antimicrobial-resistance-programme" source="Orion">Antimicrobial Resistance Programme</keyword> at Penta - Child Health Research. "By achieving global consensus, we can streamline the process of antibiotic development, allow for faster access to antibiotics, and reduce the burden of AMR on the vulnerable neonatal population," added <keyword id="1651099" type="General" weightage="50" keywordseo="manica-balasegaram" source="Orion">Manica Balasegaram</keyword>, Executive Director of GARDP. The report also highlights how collaborative antibiotic development and access network specifically targeting newborns could also prove valuable compared to single independent studies. A successful example, the authors noted, has been the collaboration between GARDP, Penta - Child Health Research, SGUL, and other partners on a recent global observational study of 3,200 babies with neonatal sepsis across 19 hospitals in 11 countries. They are also partnering on an upcoming clinical trial, which will start in South Africa within the next few months before being expanded to other countries. Despite a rising number of newborn deaths caused by AMR, very few effective antibiotics have been adequately studied to treat serious bacterial infections such as neonatal sepsis, the authors said. As many as 40 antibiotics approved for use in adults since 2000, only four have included dosing information for newborns in their labels, they said. According to the report, ethical concerns, logistical issues and regulatory requirements have made it difficult to conduct clinical research in newborns. There is a long delay in completing paediatric regulatory studies and they are also not harmonised globally to demonstrate clinical utility in newborns, it said. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/ces-2023-dates-news-products-and-what-to-expect/articleshow/96591686.cms">All-new Apple CarPlay features to AI for automobiles — here are some car technologies expected to arrive in 2023</a> <a href="https://www.businessinsider.in/tech/news/ces-2023-dates-news-products-and-what-to-expect/articleshow/96591686.cms">CES 2023: Dates, news, products, and what to expect</a>

Urgent need to develop antibiotics for newborns say global experts

There is an urgent need to develop antibiotics for newborn babies, a population that is particularly vulnerable to antibiotic resistance, according to leading global public health experts including those from India. Recent estimates show about 2.3 million newborns die of severe bacterial infections each year while an increasing number are becoming resistant to currently used antibiotics, the experts said in a report published in the December 2022 Bulletin of the <keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword>. Over the last decade, <keyword id="149212" type="General" weightage="80" keywordseo="amr" source="Orion">AMR</keyword> has worsened to the point where around 50-70 per cent of common pathogens show a high degree of resistance to available first and second-line antibiotics, they said. The paper is co-authored by international experts in the field of antimicrobial resistance (AMR), including those from the Global Antibiotic Research &amp; Development Partnership (GARDP) and the <keyword id="6365231" type="General" weightage="50" keywordseo="all-india-institute-of-medical-sciences" source="Orion">All India Institute of Medical Sciences</keyword> (<keyword id="40458" type="General" weightage="50" keywordseo="aiims" source="Orion">AIIMS</keyword>). The authors noted that despite substantial progress in medical research and a steep decline in the number of children under the age of five who die of preventable diseases, many problems related to child health remain to be tackled. Severe bacterial infections are one of them. "There is an urgent need to identify high-priority antibiotics to understand which ones work best and safely in children, and then make them available where they are needed," said <keyword id="15914044" type="General" weightage="50" keywordseo="mike-sharland" source="Orion">Mike Sharland</keyword> from St George's, <keyword id="125994" type="General" weightage="50" keywordseo="university-of-london" source="Orion">University of London</keyword> (SGUL), and member of the <keyword id="15914043" type="General" weightage="50" keywordseo="antimicrobial-resistance-programme" source="Orion">Antimicrobial Resistance Programme</keyword> at Penta - Child Health Research. "By achieving global consensus, we can streamline the process of antibiotic development, allow for faster access to antibiotics, and reduce the burden of AMR on the vulnerable neonatal population," added <keyword id="1651099" type="General" weightage="50" keywordseo="manica-balasegaram" source="Orion">Manica Balasegaram</keyword>, Executive Director of GARDP. The report also highlights how collaborative antibiotic development and access networks specifically targeting newborns could also prove valuable compared to single independent studies. A successful example, the authors noted, has been the collaboration between GARDP, Penta - Child Health Research, SGUL, and other partners on a recent global observational study of 3,200 babies with neonatal sepsis across 19 hospitals in 11 countries. They are also partnering on an upcoming clinical trial, which will start in South Africa within the next few months before being expanded to other countries. The authors said that despite a rising number of newborn deaths caused by AMR, very few effective antibiotics have been adequately studied to treat serious bacterial infections such as neonatal sepsis. As many as 40 antibiotics have been approved for use in adults since 2000, but only four have included dosing information for newborns in their labels, they said. According to the report, ethical concerns, logistical issues and regulatory requirements have made it difficult to conduct clinical research on newborns. There is a long delay in completing paediatric regulatory studies and they are also not harmonised globally to demonstrate clinical utility in newborns, it said. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/indias-agrochemicals-industry-to-see-double-digit-growth-in-fy23-and-fy24-on-strong-exports-boost-says-crisil/articleshow/96572842.cms">India’s agrochemicals industry to see double-digit growth in FY23 and FY24 on strong exports boost, says Crisil</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/from-egypt-to-belarus-countries-that-are-covid-free-amid-a-global-rise-in-cases/slidelist/96591191.cms">From Egypt to Belarus: Countries that are Covid free amid a global rise in cases</a>

The nurses <keyword id="6357801" type="General" weightage="100" keywordseo="union" source="Orion">union</keyword> of <keyword id="6365231" type="General" weightage="50" keywordseo="all-india-institute-of-medical-sciences" source="Orion">All India Institute of Medical Sciences</keyword> (<keyword id="40458" type="General" weightage="80" keywordseo="aiims" source="Orion">AIIMS</keyword>) on Tuesday began an indefinite strike after the union's president Harish Kajla was suspended by hospital administration. Nursing Officer Harish Kumar Kajla was suspended with immediate effect on Monday night in view of the April 22 incident of disrupting OT patient services. The union is seeking immediate revocation of suspension of Kajla and stopping of all kinds of retaliative measures against union executives and union members of main OT. "In response to your unilateral decision to suspend Harish Kajla, president of AIIMS Nurses Union, without even citing proper reasons, the union has called an emergency executive meeting and decided to go on indefinite strike from 8 a.m., 26/4/2022 demanding immediate revocation of suspension of Harish Kumar Kajla and stopping of all kinds of retaliative measures against union executives and Union members of main OT", said nurses union in a letter to AIIMS director Randeep Guleria. In a statement, the union said: "The union has always been receptive and open to expressing our genuine concerns and version throughout this issue. But unfortunately, we were neither called, nor contacted via any communication which forced us to go on an indefinite strike to safeguard the basic rights of our members." However, the AIIMS <keyword id="6474499" type="General" weightage="50" keywordseo="rda" source="Orion">RDA</keyword> said that the suspension of Kajla is an action taken against his misbehaviour and the use of abusive language against a resident doctor. "Whoever is diverting this matter for political gain , be aware that the RDA, AIIMS is going to fight for the self respect of residents always", said RDA AII SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/politics/india/news/real-time-payments-are-forecast-to-boost-indian-gdp-by-us-45-9-billion-in-2026/articleshow/91093163.cms">Real-time payments are forecast to boost Indian GDP by US $45.9 billion in 2026</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/25-40-of-people-with-covid-19-develop-long-covid-reporting-symptoms-that-affect-multiple-organs-and-cause-mental-health-issues-study/articleshow/91093962.cms">25-40% of people with COVID-19 develop long Covid, reporting symptoms that affect organs and cause mental health issues : Study</a>

AIIMS nurses' union goes on indefinite strike after suspension of its president

Two doses of <keyword id="9485939" type="General" weightage="20" keywordseo="Covaxin" source="Orion">Covaxin</keyword> are 50 per cent effective against symptomatic COVID-19, according to the first real-world assessment of India's indigenous coronavirus vaccine published in <keyword id="456544" type="General" weightage="20" keywordseo="The-Lancet" source="Orion">The Lancet</keyword> Infectious Diseases journal. The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns. The latest study assessed 2,714 hospital workers at the <keyword id="6365231" type="General" weightage="20" keywordseo="All-India-Institute-of-Medical-Sciences" source="Orion">All India Institute of Medical Sciences</keyword> (AIIMS) in Delhi, from April 15 May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection. Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases. Covaxin, developed by Hyderabad-based <keyword id="149108" type="General" weightage="20" keywordseo="Bharat-Biotech" source="Orion">Bharat Biotech</keyword> in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart. In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. The World Health Organization (WHO) added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. The latest study was conducted during India's second COVID-19 surge and in healthcare workers who were primarily offered Covaxin. "Our study offers a more complete picture of how BBV152 (Covaxin) performs in the field and should be considered in the context of COVID-19 surge conditions in India, combined with the possible immune evasive potential of the Delta variant," said Manish Soneja, Additional Professor of Medicine at AIIMS New Delhi. "Our findings add to the growing body of evidence that rapid vaccine rollout programmes remain the most promising path to pandemic control while public health policies must continue to include additional protective measures, such as mask-wearing and social distancing," Soneja said in a statement. The COVID-19 vaccination centre at AIIMS New Delhi exclusively offered Covaxin beginning January 16 this year to all of its 23,000 employees. Researchers evaluated the effectiveness of the vaccine against symptomatic RT-PCR confirmed SARS-CoV-2 infection. Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2, the virus that causes COVID-19, and 1,097 tested negative. Positive cases were matched to negative RT-PCR tests (controls). The odds of vaccination with Covaxin were compared between cases and controls and adjusted for occupational exposure to COVID-19, previous SARS-CoV-2 infection, and infection dates. The study found that the vaccine effectiveness against symptomatic COVID-19 after two doses of Covaxin with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent. The effectiveness of two vaccine doses remained stable over the seven-week follow-up period, the researchers said. The adjusted vaccine effectiveness of the first dose, estimated after seven and 21 days, was low, which is consistent with the performance of other preventives against the Delta variant, they said. "Findings from the study confirm previous research indicating that two doses of BBV152 are required to achieve maximum protection and that all vaccine roll-out plans must follow the recommended dosing schedule," said Parul Kodan, Assistant Professor of Medicine at AIIMS New Delhi. "More research is needed to better understand how these findings translate to BBV152's effectiveness against delta and other variants of concern, especially related to severe COVID-19 infection, hospitalisation, and deaths," Kodan said. The authors acknowledge that the vaccine <keyword id="12595121" type="General" weightage="20" keywordseo="effectiveness-of-Covaxin" source="Orion">effectiveness of Covaxin</keyword> estimated in this study is lower than the efficacy reported by the recently published phase 3 trial. They noted that several factors may be responsible for the lower vaccine effectiveness in the latest study. The researchers said this study population only included hospital employees who may have a higher risk of exposure to COVID-19 infection than the general population. The research was conducted during the peak of India's second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said. Prevalence of circulating variants of concern, especially Delta, may have also contributed to the vaccine's lower effectiveness, according to the researchers. The authors acknowledge several limitations to their study. The study does not estimate the vaccine effectiveness against hospitalisation, severe disease, and death, which require further assessment, they noted. Also, the study was not designed to estimate vaccine effectiveness for different time intervals after vaccination or to determine if vaccine effectiveness changed over time, the researchers added. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/url-go-fashion-ipo-allotment-tomorrow-and-gmp-is-falling-every-day/articleshow/87876496.cms">Go Fashion IPO allotment tomorrow; GMP on a downward trend</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/if-you-missed-tarson-products-ipo-allotment-heres-what-you-should-know/articleshow/87870822.cms">If you missed Tarson Products’ IPO allotment, here’s what you should know</a>

Covaxin shows 50% effectiveness against symptomatic COVID-19 in real-world assessment, says Lancet study

The <keyword id="6365231" type="COMPANY" weightage="20" keywordseo="all-india-institute-of-medical-sciences">All India Institute of Medical Sciences</keyword> (<keyword id="40458" type="COMPANY" weightage="20" keywordseo="AIIMS">AIIMS</keyword>) is learnt to have started screening of children aged 6-12 years for the clinical trials of <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword>'s first indigenously developed Covid-19 vaccine, <keyword id="149108" type="COMPANY" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword>'s <keyword id="9485939" type="PERSON" weightage="20" keywordseo="covaxin">Covaxin</keyword>. Sources said that the recruitment and clinical trials of the children aged 6-12 years will start from Tuesday. The trial on children aged 6-12 has already started at AIIMS Patna. Participants would be given the vaccine after their screening report comes. The trial would ensure if the Bharat Biotech jab is suitable for children. Delhi AIIMS has decided to start the trial drive after the recruitment and <keyword id="122283" type="PERSON" weightage="20" keywordseo="Clinical-trial">clinical trial</keyword> for single-dose Covaxin for 12-18 age group is over. After the recruitment of 6-12 year-old children, AIIMS Delhi will be conducting trials for the age group 2-6 years of children. The trials are taking place at 525 centres. The screening of children for the trial of single-dose Covaxin among those aged between 2 and 18 years started at the AIIMS in <keyword id="6358777" type="LOCATION" weightage="20" keywordseo="New-Delhi">New Delhi</keyword> on June 7 after India's drug regulator had granted permission for conducting the Phase 2 and 3 clinical trials of Covaxin in the age group 2 to 18 years on May 12. AIIMS Patna, Mysore Medical College and Research Institute in Karnataka have also been selected to conduct clinical trials on children. Covaxin is being used on adults in India's ongoing Covid-19 vaccination drive since January 16 this year. The government last week cautioned that even though Covid-19 has not taken a serious shape among children till now, its impact can increase among them if there is a change in virus behaviour or epidemiology dynamics, and said preparations are being strengthened to deal with any such situation. A national expert group has been formed to review Covid-19 infections in children and approach the pandemic in a renewed way to strengthen the nation's preparedness, <keyword id="2665691" type="COMPANY" weightage="20" keywordseo="Niti-Aayog">NITI Aayog</keyword> Member (Health) V.K. Paul had said at a press conference. "The group has examined signs which were not available four-five months before." SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/sona-comstar-ipo-price-gmp-should-you-subscribe/articleshow/83505013.cms">Sona Comstar IPO worth ₹5,550 crore opens today – find out if this EV battery player has enough juice for a long ride</a> <a href="https://www.businessinsider.in/business/news/why-dodla-dairy-has-no-plans-to-expand-beyond-southern-india/articleshow/83503817.cms">Here’s why Dodla Dairy has no plans to expand beyond southern India for at least the next two years even with its IPO</a> <a href="https://www.businessinsider.in/stock-market/news/adani-group-under-sebi-scanner-on-market-manipulation/articleshow/83501698.cms">Gautam Adani loses over $7 billion in net worth after questions over the meteoric rise in group stocks</a>

You Searched For "all india institute of medical sciences" and got 6 results

High fat, low carb diet along with medicines can cut seizures by half: AIIMS study

PTI

Urgent need to develop antibiotics for newborns say global experts

PTI

Urgent need to develop antibiotics for newborns say global experts

PTI

AIIMS nurses' union goes on indefinite strike after suspension of its president

IANS

Covaxin shows 50% effectiveness against symptomatic COVID-19 in real-world assessment, says Lancet study

PTI

AIIMS Delhi to start clinical trial of Covaxin on children aged 6-12 years from Tuesday

IANS

Popular Keywords

Buying Guides